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Fingerprinting
Cancer
Development
In the world of cancer, early detection is crit-
ical for successful treatment, but early diag-
nostic tools are in woefully short supply.
Among ovarian cancer patients, for example,
80% of cancers are diagnosed at a late stage,
and, as a result, only 35% of patients
live past five years. Now the Clinical
Proteomics Program is blending pro-
teomics (the study of proteins in liv-
ing cells) and clinical cancer research,
with the goal of diagnosing cancer ear-
lier, then tailoring drugs to precisely
attack tumors with the fewest side
effects for patients. 
The effort, begun two years ago, is
a joint effort of the U.S. Food and
Drug Administration and the National
Cancer Institute. It is codirected by
Emanuel Petricoin, a biochemist at the
Food and Drug Administration Center
for Biologics Evaulation and Research
in Rockville, Maryland, and Lance
Liotta, chief of the Laboratory of
Pathology at the National Cancer
Institute Center for Cancer Research in
Bethesda, Maryland. 
Whereas genomics deciphers infor-
mation stored in DNA, proteomics
looks at proteins, which carry out the
body’s complex functions. Program sci-
entists focus on how proteins signal
each other and interact in so-called cel-
lular circuits to find key “nodes” to tar-
get with drugs. These nodes are critical
intervention points in the pathways
involved in cancer, spots at which a
drug could be used to block a key pro-
tein to prevent unwanted events (such
as abnormal cell growth) from happen-
ing downstream. 
The team designs special protein
microarrays to detect specific phospho-
proteins, which regulate early steps in
cancer progression. These protein
microarrays detect 50–100 key proteins at a
time. “The only way to know if a pathway
is [activated or not] is to measure proteom-
ic levels,” says Petricoin. Through this pro-
teomics approach, program scientists hope
to pinpoint key phosphoproteins that
could, for instance, be controlled with a
specific drug to block tumor growth with
few side effects, as opposed to poisoning
both tumors and healthy cells with the
harsh chemotherapy drugs used now.
Protein microarrays have helped the
team answer a central question in prostate
cancer biology: Are rapidly growing tumor
cells caused by an increase in growth rate or
by a decrease in cell death rate (apoptosis)?
In  a study published in the September
2002 issue of Nature Reviews Drug
Discovery, cell growth and apoptosis path-
ways were compared in normal, premalig-
nant, and invasive carcinoma cells in
prostate tumor samples. The researchers
found that apoptosis signals were primarily
suppressed in early carcinogenesis. “This
gives clues about how to treat early
lesions,” says Petricoin. For example,
depending on the proteins found to be
important, drugs could be tailored to stim-
ulate apoptosis to remove abnormal cells,
or to block cell proliferation to prevent
tumor growth, or to impede the growth of
blood vessels that feed tumors.
Target cells for protein microarrays are
gathered using laser-capture microdissec-
tion, a technology developed in the late
1990s to tease out normal, premalignant,
and tumor cells from tissue samples. In this
type of microscopy, a plastic film is sus-
pended a few microns from the microscope
slide holding stained cells. When activated
by a laser, the plastic film melts, forming a
bulge that drops and plucks cells out of the
tissue section, explains Petricoin. The
cells on the slide are viewed on a com-
puter monitor, and scientists home in
on them with a joystick “like in a com-
puter game,” he says. 
Protein microarrays show patterns,
or fingerprints, that identify early-stage
cancer or monitor toxic effects of
drugs. Petricoin and his colleagues are
searching for fingerprints in blood that
reflect cancerous processes before
tumors are visible. In a study published
in the 16 February 2002 issue of The
Lancet, they used protein microarrays to
analyze blood samples from 50 ovarian
cancer patients and 66 healthy controls,
and correctly singled out all 50 cancer
patients and 95% of the controls.
Proteomic fingerprints also detect
heart toxicity, a common side effect of
the cancer drug doxorubicin. In collab-
oration with Frank Sistare, acting direc-
tor of the Office of Testing and Research
at the Food and Drug Administration
Center for Drug Evaluation and Re-
search, the team obtained preliminary
results from a rat model showing that
cardiotoxicity was detected 90% of the
time before clinical symptoms occurred.
“We’re trying to find a fingerprint in a
drop of blood that identifies early
[heart] damage,” says Petricoin. Such a
fingerprint could identify susceptible
patients, who could then be switched to
another treatment. 
Brian Leyland-Jones, a professor of
oncology at McGill University in
Montréal, Québec, agrees that sam-
pling blood would be a much prefer-
able means for early detection of cancer.
Right now, he says, all known biomarkers
must be obtained by the far more invasive
sampling of tumor tissue. He adds that
new tests based on blood samples “offer
the ability to find tumors early on and
choose the best customized treatment for
each patient.” –Carol Potera
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Environews Forum
Care more for the individual patient than 
for the special features of the disease. 
Sir William Osler, Canadian physician/anatomist (1849–1919)
Microwonders. Protein microarrays are being more widely used
to uncover the mechanisms of cancers such as prostate cancer
(top) and ovarian cancer (bottom), in hopes of targeting inter-
vention in disease development.Forum
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The EGP at Five
Years
More than 100 scientists, public health pro-
fessionals, and physicians gathered in
Boston 7–9 June 2003 for a symposium,
Genes, Environment, and Disease, that pro-
vided research updates on the NIEHS
Environmental Genome Project (EGP) and
its associated Comparative Mouse Gen-
omics Centers Consortium (CMGCC).
The EGP was initiated in 1998 with a
dual goal: providing information on
how individual genetic differences affect
disease risk from environmental agents,
and proposing appropriate environmen-
tal policies in response to that informa-
tion. In embarking on that quest, the
NIEHS divided the work into a number
of subject areas ranging from the identi-
fication of variations in environmental
response genes to the broad examination
of the ethical, legal, and social implica-
tions of the findings of the EGP. 
The symposium occurred only weeks
after completion of Phase 1 of the EGP,
which called for the resequencing of
more than 200 environmentally respon-
sive genes for the purpose of identifying
single-nucleotide polymorphisms, or
SNPs, that are important in determining
disease susceptibility. The mission of
Phase 2, which is currently under way
and expected to extend to 2004, is to
conduct functional analysis studies to
characterize the SNP variants discovered
in Phase 1. Phase 3 of the EGP, now in
its initial planning stages, will include
the Molecular Epidemiology Program,
in which population-based epidemiologic
studies will be initiated to understand the
role of gene variations in human genetic
susceptibility.
Because animal models are an essential
part of Phase 2, the NIEHS created the
CMGCC, which consists of five universi-
ties. The consortium is charged with devel-
oping mouse models containing, among
other SNPs, the human polymorphisms
identified in Phase 1. The focus to date has
been on modeling mice with variants in
environmentally responsive cell cycle and
DNA repair genes. 
At the symposium, NIEHS deputy direc-
tor Samuel Wilson said that “all of us at the
[NIEHS] are very pleased” with the work
done so far. But he also suggested that much
work lies ahead and warned against suc-
cumbing to pressure brought by the public
or the media, who may be anxious to see
genetically based disease cures. “It’s too easy
to fall into the trap of ‘tell me what it means
next week,’” he said. “It’s an ongoing activi-
ty we’re talking about. We’re not looking to
an end point of five years or even fifty years.”
He  emphasized the importance of sound
polymorphic studies, because “otherwise
we’ll be doing superficial science.”
Joan Packenham, the NIEHS program
director for the CMGCC, and Kimberly
Gray, a health science administrator with
the institute’s Susceptibility and Pop-
ulation Health Branch, presented over-
views of various facets of the EGP. They
were followed by CMGCC directors Raju
Kucherlapati of Harvard Medical School
and Jan Vijg of the University of Texas
Health Science Center at San Antonio,
who described consortium accomplish-
ments. For example, the CMGCC recent-
ly launched the Mouse Federated Database,
an integrated bioinformatics tool that
allows access to the biological data on
CMGCC mouse models. Richard Sharp, an
assistant professor of medicine at the Baylor
College of Medicine, gave an introductory
talk about the ethical, legal, and social
implications of the EGP, discussing privacy
issues arising from individual participation
in research and protection of racial or eth-
nic groups in which certain genetic variants
may be more common.
The balance of the agenda was devoted
to presentations by researchers working on a
variety of studies related to the scientific
interests of the EGP. For example, Jeanne
Manson, a research scientist in human gen-
etics and molecular biology at the Chil-
dren’s Hospital of Philadelphia, described
her work to identify and evaluate risk factors
for hypospadias (an abnormality of the ure-
thral opening on the penis) in 250 fam-
ilies to date. Among her findings, she
said, are a relationship between hypospa-
dias and exposure to pesticides, paints
and stains, fuels, and solvents. Susan L.
Lindquist, director of the Whitehead
Institute for Biomedical Research in
Cambridge, Massachusetts, reported on
her research on prion proteins in baker’s
yeast. Prions self-perpetuate by inducing
other proteins to assume their same
shape. The research, she said, has
advanced understanding of mammalian
prions, which cause spongiform enceph-
alopathies that can spread through the
environment.
Packenham said the symposium was
intended to make the scientific commu-
nity aware of research being conducted
within the EGP and the consortium, and
was organized specifically to bring
together scientists from two different
communities under the EGP: mouse
modelers and epidemiologists.
One of those mouse modelers,
David Johnson, director of the Uni-
versity of Texas M.D. Anderson
Cancer Center Comparative Mouse
Genomics Center in Smithville,
agreed, pointing out that the utility of the
two disciplines meeting with each other
went beyond just mutual edification. “We
could see where we could help each other,”
he said. “We [mouse people] needed help
identifying which SNPs to model, for
instance. And [the epidemiologists] were
interested in what we’ve already found so
they can identify the most promising
SNPs to do association studies with.”
He  also noted that there are certain
big-picture benefits to meeting with other
scientists working within the broad EGP.
“I got a much clearer picture of what the
overall Environmental Genome Project is
and how we fit in,” he said. “I also got an
idea about how much progress has been
made.” –Richard Dahl
ENVIRONMENTAL DISEASE
Uncovering connections. At a recent meeting on the EGP,
scientists reported findings on diseases with possible
gene–environment interactions, such as spongiform enceph-
alopathies, caused in part by prion proteins.A 574 VOLUME 111 | NUMBER 11 | August 2003 • Environmental Health Perspectives
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Genes and
Environment: 
A SNPshot
Have you ever heard someone try to dispel
concern about their smoking by describ-
ing elderly relatives who were lifelong
smokers? This gambit usually fails, but
there actually is something to the excuse.
Increasingly, researchers are un-
covering the extent to which
genes control susceptibility and
vulnerability to environmental
health hazards including ciga-
rette smoke, toxic chemicals,
alcohol, and more.
Understanding why individu-
als react differently to the same
chemicals requires analysis of dif-
ferences in their genetic makeup.
Single-nucleotide polymorphisms
(SNPs) are the simplest differences
to examine on the wide scale,
agreed participants at Genetic
Variation and Gene–Environment
Interaction in Human Health and
Disease, a seminar held 16 April
2003 at the NIH campus in
Bethesda, Maryland. The NIEHS,
the National Human Genome
Research Institute, and the
National Institute on Alcohol
Abuse and Alcoholism sponsored
the seminar, which was part of an
NIH conference marking the 50th
anniversary of the discovery of the
chemical structure of DNA and
the recently completed sequencing
of the human genome. 
Pinpointing long-term expo-
sure to cancer-causing agents in
the environment can be extreme-
ly difficult due to challenges such as the
near-impossibility of determining a per-
son’s diet or occupational exposures over
many years. SNPs, on the other hand, are
abundant and traceable, said seminar par-
ticipant Martyn Smith, a toxicologist at
the University of California, Berkeley,
School of Public Health and director of the
university’s NIEHS-sponsored Environ-
mental Health Sciences Center. Smith said
functional SNPs are likely to explain the
majority of people’s susceptibility.
A typical gene of 30,000 base pairs
has 150 SNPs, noted Deborah Nickerson,
a geneticist at the University of Washing-
ton in Seattle. Most SNPs have little or
no effect on human health. But some
greatly influence disease risk. SNPs near
one another in the genome can be related,
forming blocks in a gene and potentially
making it easier to trace susceptibilities in
the general population. Only days prior
to the seminar, Nickerson discovered
such blocks in the BRCA1 breast cancer
gene, which will make it easier for
researchers to understand the role of
BRCA1 in breast cancer development in
women who don’t have rare inherited
mutations in this gene. 
Smith and collaborators in Leeds,
England, are looking for SNPs that confer
leukemia susceptibility. Most cases of
leukemia arise from gene–environment
interactions, he told seminar participants.
In  the early 1990s, scientists discovered
that a SNP on the NQO1 gene increases
the risk of benzene-induced leukemia.
This led Smith and colleagues to propose
that chemicals that cause oxidative stress
and that are detoxified by NQO1, such as
benzene and flavonoids in high doses, may
increase the risk of myeloid leukemia.
They also suggest that low folate intake
increases the risk of lymphocytic leukemia
in adults and children, whereas certain
SNPs in folate-metabolizing genes decrease
the risk. They are looking at SNPs in genes
involved in apoptosis and DNA repair in
relation to leukemia risk, and are further
expanding their research to the study of
lymphoma.
Clement Furlong, a geneticist at the
University of Washington in Seattle,
reported that some people are more sensi-
tive to insecticides and possibly nerve
agents because of genetic variability in the
gene that regulates production of the
enzyme paraoxonase-1 (PON1). PON1
oxidizes lipids, metabolizes organophos-
phates, and activates or inactivates medica-
tions including statins, glucocorticoids,
and antibiotics.
Furlong cited research from
the 15 June 1999 issue of Tox-
icology and Applied Pharmacol-
ogy showing that veterans who
suffered from Gulf War syn-
drome had low PON1 levels.
Other studies have shown that
injecting purified PON1 into
mice without the PON1 gene
protects them against chemical
assault. Furlong is confident
that injections of engineered
recombinant PON1 will some-
day be similarly used to detoxify
humans who have been exposed
to organophosphates.
Major advances in molecular
methods now enable researchers
to rapidly sequence whole
genomes and associate SNPs with
specific diseases. “We spent
many, many years uncovering
about a dozen polymorphisms in
the [PON1] gene,” Furlong said
at a press conference following
the seminar. But thanks to revo-
lutionary new technologies, in
just the last couple of months
Nickerson and her group have
identified more than 150 addi-
tional PON1 polymorphisms. In
a matter of days, she sequenced
the entire PON1 gene from four
individuals suspected of having sequence
variations and then identified those varia-
tions, Furlong said.
At the postseminar press conference,
NIEHS director Kenneth Olden an-
nounced the completion of the first phase
of the institute’s Environmental Genome
Project, which seeks to identify genetic vari-
ations among individuals that make them
more vulnerable to environmental agents.
Research in this phase focused on finding
common sequence variations in human
genes involved in DNA repair and cell cycle
pathways. Future goals involve studying
apoptosis, homeostasis, and drug-metabo-
lizing genes, all of which are thought to play
a role in vulnerability to environmental
exposure. –Tina Adler
MEETING REPORT
Small changes, big differences. Single-nucleotide polymorphisms are
the starting point for investigating genetic variation in response to envi-
ronmental exposures.Forum
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The Pharmacogenetics Research Network and the
Pharmacogenetics and Pharmacogenomics Knowledge Base
txgnet
In the United States, much of the pharmacogenetics research sponsored by the federal government is over-
seen by the Pharmacogenetics Research Network (PGRN). Formed three years ago, the PGRN is based at the
National Institute of General Medical Sciences and counts among its programs research being done at five
other NIH institutes and eight universities. The PGRN website, located at http://www.nigms.nih.gov/
pharmacogenetics/, provides a comprehensive overview of the network’s projects and activities. 
The Research Network page features a complete listing of PGRN scientists, with links to profiles of their
projects. Each profile includes links to the member’s website, investigator contact information, a synopsis
of the member’s work to date, and a link to all submissions the member’s group has made to the
Pharmacogenetics and Pharmacogenomics Knowledge Base
(PharmGKB). Also on the Research Network page is informa-
tion on the governing structure of the PGRN, including net-
work policy statements and links to contact information for
its steering and other committees, PGRN interest groups, and
the network’s industry liaison group. Links to summaries of
industry liaison group meetings are also available.
The Ethics & Communities page describes the work of the
Populations Advisory Group, which was established by the National Institute of General Medical Sciences to
consider the possible ethical and legal impact of pharmacogenetics research. The page is stocked with the
group’s reports to date as well as summaries of ongoing studies in this area and a paper on points to con-
sider when planning genetic research involving a community setting. 
The site’s News & Events page offers links to information on the PGRN’s annual meetings. These one-
day meetings, the next of which will be held 8 March 2004 in Los Angeles, California, feature morning
keynote sessions followed by an afternoon of presentations by network members on their latest scientific
findings. Full meeting reports from previous meetings are available on the site. The News & Events page
also features PGRN press releases detailing the growth of the network’s membership and offering insight
into other significant milestones of the group.
The Related Resources page includes links to two NIH brochures on pharmacogenetics. Medicines for
YOU describes pharmacogenetics in general and tells how it is used in drug development. Genes &
Populations explains genetic research for the layperson and tells how this research sometimes focuses on
specific population subgroups to study genetic differences. Both brochures are also available from the site
in Spanish. Other links lead to the Department of Energy’s site on pharmacogenomics, the Pharmaceutical
Research and Manufacturers of America’s genomics resource guide, the Human Genetic Cell Repository,
dbSNP (a database of single-nucleotide polymorphisms), the Protein Data Bank, and PharmGKB.
PharmGKB, an integrated data resource that supports and consolidates the findings of the PGRN, is
housed at Stanford University’s Department of Genetics; its website is located at http://www.pharmgkb.org/.
PharmGKB accepts data from scientists
both within and outside of the PGRN.
Data are organized into searchable cate-
gories according to the type of
gene–drug relationship studied: clinical
outcomes, pharmacodynamics and drug
responses, pharmacokinetics, and molecular and cellular functional assays. Visitors to the site can also
search for data by other categories including genes with primary data, genes with variant data, drugs
with primary data, all diseases, and all pathways, as well as by project.
The Overview page provides background information on the project, while annual newsletters, site
and citation advisories, and PharmGKB usage policies are available through the bar at the top of the
homepage. The Projects page describes two efforts that are ongoing within the group. The PharmGKB
Community Project allows scientists to deposit verifiable information on gene–drug relationships that
would be classified as phamacogenetic. The Pharmacogenetics Ontology Project is working to develop
a standardized mechanism for organizing and annotating pharmacogenetic information. 
Researchers and others can find links to a number of useful web-based resources on the Resources
page. Among these are the Classification of Expression Array (Cleaver) site, the Environmental Genome
Project’s GeneSNP site, PHASE (a program used to reconstruct haplotypes), and the Cytochrome P450 Drug
Interaction Table. Following the Education link at the top of the Tools page takes visitors to a list of other
useful resources, including an overview of pharmacogenetics as illustrated using the Asthma Case Study
and the CYP2D6 Study, and a link to the Minority Pharmacogenomics website. –Erin E. DooleyA 576 VOLUME 111 | NUMBER 11 | August 2003 • Environmental Health Perspectives
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A Big Circuit Model
You can call it metabolic profiling,
metabonomics, or metabolomics; one
speaker at a recent conference called it
“biochemistry grown up.” Scientists aren’t
settled on exactly what to call it, but this
addition to the growing list of “-omics”
subspecialties is rapidly gaining accept-
ance as a vital link in the chain of knowl-
edge starting at the genome and ending at
the whole human body and how it is
affected by its environment.
The field’s identity crisis did not damp-
en the enthusiasm of the more than 185
participants at Metabolic Profiling: Ap-
plications to Toxicology and Risk Re-
duction, a conference held 14–15 May
2003 at the NIEHS in Research Triangle
Park, North Carolina. The meeting
brought together molecular biologists, ana-
lytical chemists, toxicologists, clinicians,
nutritional scientists, and computational
biologists from government, academia,
and industry to assess the current state of
the science in the emerging area of meta-
bolic profiling, and to define its potential
applications to the health sciences. It was
organized by the NIEHS, the National
Institute of Diabetes and Digestive and
Kidney Diseases, the NIH Office of Rare
Diseases, the U.S. Food and Drug Ad-
ministration, Paradigm Genetics, and
Waters Corporation.
In metabonomics, biofluids and tissues
are analyzed to determine the metabolites
present, both in homeostasis and when the
organism has been affected by factors such
as environmental exposures. “It is both a
systems biology and a dynamic approach,”
said speaker  Hector Keun, a postdoctoral
researcher at Imperial College of the
University of London, “as metabonomics
analysis can provide a description of the
integrated physiological behavior of an
entire living system across time.” 
Metabolic profiling is a hugely complex
undertaking, generating huge amounts of
data to be analyzed and mined for nuggets
of significant information about metabol-
ic pathways and networks, novel biomark-
ers, and how metabolites interact not only
with genes and proteins, but also with
environmental, nutritional, and lifestyle
factors. 
The integration of this dizzying array
of variables holds the potential to tell
researchers a great deal about human
health and disease etiology, with transla-
tional rewards already emerging in diag-
nostics and drug targeting, development,
and safety screening. “Metabolism is pheno-
type,” said Steve Watkins, president of
Lipomics Technologies of West Sacra-
mento, California. “It integrates all the 
factors you’d want to know about, from
nutrition to environment to genetics; it’s
really the only way to assess how you’re
doing as an individual. If you want to assess
your current state of health, you have to
[study] the metabolome.”
Lipomics Technologies has developed
a quantitative assay that measures several
hundred lipid metabolites from biosam-
ples. The assay is used to study the role of
lipid metabolism in disease and develop
diagnostic profiles of drug safety and effi-
cacy. A Research Triangle Park company,
Metabolon, has identified a metabolic sig-
nature for amyotrophic lateral sclerosis.
This profile holds great promise for iden-
tifying disease-related biochemical and
signaling events, diagnostic markers, and
potential therapies.
Metabolic profiling technology is
booming in both the analytical and com-
putational realms, but the metabolome is
only one element of the entire picture. “If
you want to learn about pathways,” said
Trey Ideker, Pfizer Computational
Biology Fellow at the Whitehead Institute
for Biomedical Research in Cambridge,
Massachusetts, “you’re going to have to
characterize metabolites, genes, and pro-
teins, and for each we have interactions
METABONOMICS
Systemic perspective. Metabonomics, the analysis of metabolites, offers a new tool for describing
the genomic network of the body.and levels. That’s six different things we’re
going to have to integrate together in a
big circuit model, or blueprint, of the
cell, and of every cell type, and of every
tissue type.” The key to meeting this huge
challenge, he said, is data mining.
Ideker described work being con-
ducted by his group in developing a
computational “scaffold” approach to
modeling complex cellular interactions.
The modeled scaffolds are mined to re-
veal a hierarchy of signaling, regulatory,
and metabolic pathways. Keun told par-
ticipants of a system to analyze metabol-
ic profiling data being constructed by
the Consortium on Metabonomic
Toxicology, a project of scientists at six
pharmaceutical companies and Imperial
College. The consortium’s prototype has
already shown promise in elucidating
the nature of the relationships between
traditional toxicological end points and
metabolic descriptors, helping to vali-
date the role of metabonomics data in
predictive and mechanistic toxicology.
Scientists expressed excitement at the
potential contributions offered by meta-
bolic profiling to toxicology, toxicoge-
nomics, and risk assessment, reduction,
and prevention. “There is some incredible
technology that can be used to assess risk,
link exposure with disease etiology, and
reduce the uncertainty of risk in the pop-
ulation,” said William Suk, director of the
NIEHS Center for Risk and Integrated
Sciences. “This is just the beginning.”
Kenneth Ramos, chairman of the
Department of Biochemistry and Molecular
Biology at the University of Louisville
Health Sciences Center and toxicoge-
nomics editor for EHP, said, “Metabolic
profiling can be a much more effective
way of communicating risk and of having
an impact on risk reduction strategies in
the future, because a metabolite is some-
thing people relate to and have a better
grasp on than genes. And of course,
metabolites ultimately being a reflection
of the genomic network, it’s probably
going to be quite significant.”
Participants agreed that perhaps the
most consequential future direction for
the field—where it will ultimately yield
its most profound benefits—lies in the
integration of metabolic profiling data
with genomic and proteomic data. “One
of the most important take-home mes-
sages from this meeting,” said Ramos, “is
the recognition that metabonomics is a
systems biology–integrated approach
that’s going to give us meaningful answers
to vitally important questions about eco-
logical and human health.” –Ernie Hood
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